These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 12089588)

  • 1. Intellectual property as a foundation for funding.
    Meltzer SL; Marks MS; McCormick JT
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE47-50. PubMed ID: 12089588
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrating the intellectual property value chain.
    Barrett B; Crawford D
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE43-6. PubMed ID: 12089587
    [No Abstract]   [Full Text] [Related]  

  • 3. Boutiques reborn in 2003.
    Surendran A
    Nat Biotechnol; 2004 Mar; 22(3):353-4. PubMed ID: 15017987
    [No Abstract]   [Full Text] [Related]  

  • 4. Big pharma wants you.
    Mack GS
    Nat Biotechnol; 2006 Nov; 24(11):1317-9. PubMed ID: 17162751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The money men.
    Alper J
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE7-12. PubMed ID: 12874970
    [No Abstract]   [Full Text] [Related]  

  • 6. Writing your business plan.
    Cohen L
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE33-5. PubMed ID: 12089584
    [No Abstract]   [Full Text] [Related]  

  • 7. Increasing number of companies found ineligible for SBIR funding.
    Bouchie A
    Nat Biotechnol; 2003 Oct; 21(10):1121-2. PubMed ID: 14520384
    [No Abstract]   [Full Text] [Related]  

  • 8. Mind the (biomedical funding) gap.
    Klausner A
    Nat Biotechnol; 2005 Oct; 23(10):1217-8. PubMed ID: 16211055
    [No Abstract]   [Full Text] [Related]  

  • 9. VC funding hits high in Q1.
    Lawrence S
    Nat Biotechnol; 2007 May; 25(5):496. PubMed ID: 17483825
    [No Abstract]   [Full Text] [Related]  

  • 10. The rise of European venture capital for biotechnology.
    Howell M; Trull M; Dibner MD
    Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356
    [No Abstract]   [Full Text] [Related]  

  • 11. Life support for life science innovation?
    Nat Biotechnol; 2007 Feb; 25(2):144. PubMed ID: 17287731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Filters for preparing to meet a venture capitalist.
    Christoffersen R
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE49-50. PubMed ID: 12874981
    [No Abstract]   [Full Text] [Related]  

  • 13. Convincing a venture capitalist to invest in your idea.
    Dooley JF; Dooley JF
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE45-8. PubMed ID: 12874980
    [No Abstract]   [Full Text] [Related]  

  • 14. Biotech IPOs--flop or pop?
    Jacobs T
    Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641
    [No Abstract]   [Full Text] [Related]  

  • 15. A counselor's dose of preventive medicine.
    Redlick D; Kapner V
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE51-3. PubMed ID: 12089589
    [No Abstract]   [Full Text] [Related]  

  • 16. Looking at US versus European exit opportunities.
    Lawrence S
    Nat Biotechnol; 2005 Oct; 23(10):1203. PubMed ID: 16302294
    [No Abstract]   [Full Text] [Related]  

  • 17. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 18. Mixed results in Q1.
    Lawrence S
    Nat Biotechnol; 2005 May; 23(5):518. PubMed ID: 15877059
    [No Abstract]   [Full Text] [Related]  

  • 19. Protecting innovation in biotechnology startups.
    Steffe EK; Shea TJ
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE51-3. PubMed ID: 12874982
    [No Abstract]   [Full Text] [Related]  

  • 20. Cash-strapped biotechs find financing alternative.
    Mitchell P
    Nat Biotechnol; 2004 Sep; 22(9):1057-8. PubMed ID: 15340452
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.